Gt Biopharma Inc (GTBP)

$3.8001

-0.17

(-4.28%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Gt Biopharma Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.8% return, outperforming this stock by 117.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.7% return, outperforming this stock by 336.3%

Performance

  • $3.80
    $3.88
    $3.80
    downward going graph

    0.0%

    Downside

    Day's Volatility :1.94%

    Upside

    1.94%

    downward going graph
  • $3.52
    $16.11
    $3.80
    downward going graph

    7.37%

    Downside

    52 Weeks Volatility :78.15%

    Upside

    76.41%

    downward going graph

Returns

PeriodGt Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
-46.1%
-0.7%
0.0%
6 Months
-47.44%
7.7%
0.0%
1 Year
-69.1%
3.3%
-1.7%
3 Years
-98.62%
13.9%
-20.7%

Highlights

Market Capitalization
5.2M
Book Value
$5.41
Earnings Per Share (EPS)
-5.58
Wall Street Target Price
150.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-55.02%
Return On Equity TTM
-79.09%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-6.8M
Diluted Eps TTM
-5.58
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-10.8
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-2.7
EPS Estimate Next Quarter
-2.7

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Gt Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3847.26%

Current $3.80
Target $150.00

Technicals Summary

Sell

Neutral

Buy

Gt Biopharma Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gt Biopharma Inc
Gt Biopharma Inc
-14.89%
-47.44%
-69.1%
-98.62%
985.74%
Moderna, Inc.
Moderna, Inc.
-2.96%
23.83%
-28.58%
-37.0%
331.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.23%
10.55%
10.52%
78.91%
167.64%
Novo Nordisk A/s
Novo Nordisk A/s
-6.56%
25.69%
48.76%
237.69%
410.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
7.86%
19.8%
79.52%
133.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gt Biopharma Inc
Gt Biopharma Inc
NA
NA
NA
-10.8
-0.79
-0.55
NA
5.41
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.8
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.3
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gt Biopharma Inc
Gt Biopharma Inc
Buy
$5.2M
985.74%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.1B
331.65%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
167.64%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
410.4%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.49%
28.42
36.68%

Institutional Holdings

  • Vanguard Group Inc

    2.62%
  • BMO Capital Markets Corp.

    1.44%
  • Bank of Montreal

    1.44%
  • Geode Capital Management, LLC

    0.81%
  • BlackRock Inc

    0.73%
  • Wells Fargo & Co

    0.73%

Corporate Announcements

  • Gt Biopharma Inc Earnings

    Gt Biopharma Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

using our proprietary platform technology, gt biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary nk cell engager (trike) platform technology. (nasdaq: gtbp)

Organization
Gt Biopharma Inc
Employees
2
CEO
Mr. Michael Martin Breen
Industry
Pharmaceuticals: Other

FAQs